Yihua Gu

Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial

Alan Menter, Stephen K. Tyring, Kenneth B. Gordon et al. · Journal of the American Academy of Dermatology · 2007 · 883 citations

Life Sciences, Dermatology, Immunology +10

Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa

Alexa B. Kimball, Martin M. Okun, David Williams et al. · New England Journal of Medicine · 2016 · 777 citations

Medicine, Dermatology, Pharmacology +16

Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials

Kenneth B. Gordon, Bruce Strober, Mark Lebwohl et al. · The Lancet · 2018 · 662 citations

Medicine, Clinical Sciences, Pharmacotherapy +11

Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials

Emma Guttman‐Yassky, Henrique D. Teixeira, Eric L. Simpson et al. · The Lancet · 2021 · 543 citations

Life Sciences, Dermatology, Pharmacotherapy +13

Adalimumab for the Treatment of Moderate to Severe Hidradenitis Suppurativa

Alexa B. Kimball, Francisco A. Kerdel, David R. Adams et al. · Annals of Internal Medicine · 2012 · 410 citations

Medicine, Clinical Sciences, Dermatology +11